[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628969":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":11,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":11},{"fullName":5,"class":6},"National Institute on Drug Abuse (NIDA)","NIH",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Treatment","EXPERIMENTAL",null,[13],"Drug: Tirzepatide",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Tirzepatide","Participants will receive weekly injections of tirzepatide 2.5 mg for 4 weeks. The dose is expected to increase by 2.5 mg every 4 weeks, however, the decision to increase the dose will be made based on the Dose Increase Checklist and shared decision between the site study physician (MD or DO) and the participant.",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"Participants will receive weekly masked injections of placebo.",[15],[29],{"name":30,"affiliation":31,"role":32},"Jia Bei Wang, MD, PhD","NIDA\u002FNIH, Division of Therapeutics and Medical Consequences (DTMC)","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Jennifer Wong, PhD","CONTACT","301-827-6267","Jennifer.Wong3@nih.gov",{"name":40,"role":36,"phone":41,"phoneExt":11,"email":42},"Jana Drgonova, PhD","301-827-5933","jana.drgonova@nih.gov",{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628969","phase-2-trial-of-tirzepatide-for-the-treatment-of-cannabis-use-disorder-100628969",false,"NCT07468552","Trial of Tirzepatide for the Treatment of Cannabis Use Disorder","Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)","Inclusion Criteria:\n\n* Between 18 and 70 years of age\n* Meets DSM-5 criteria for moderate or severe CUD\n* Interested in treatment for cannabis use disorder\n* Able to understand the study procedures and written informed consent in English\n* Willing to comply with all study procedures and medication instructions\n* If female, is not pregnant, and agrees to use acceptable birth control methods\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) ≤ 23 kg\u002Fm²\n* Presence of a medical or psychiatric disorder that contraindicates participation in the study\n* Substance use disorder other than tobacco or mild alcohol-use disorder\n* Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product\n* Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug\n* Current or recent (past 6 months) enrollment in substance use disorder treatment\n* Current or planned pregnancy and breastfeeding\n* Living or medical situation that would interfere with adherence to the study protocol","ALL","18 Years","70 Years",{"count":56,"type":57},100,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.",[63],"Cannabis Use Disorder",[65,66,67],"Cannabis Use","Cannabis Addiction","Marijuana Addiction","NOT_YET_RECRUITING","2026-03-09",{"date":71,"type":72},"2026-03-12","ACTUAL",{"date":74,"type":57},"2026-11-15",{"date":76,"type":57},"2028-11-15",{"name":5,"class":6}]